Login to Your Account



Clinic Roundup


Friday, April 12, 2013
• Cardio3 BioSciences SA, of Mont-Saint-Guibert, Belgium, published results of its Phase II (C-CURE) trial in the Journal of the American College of Cardiology showing that therapy with C3BS-CQR-2 is feasible and safe with signals of benefit in chronic heart failure, and merits further evaluation.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription